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Exercise-Induced Bronchoconstriction among Greek elite athletes: Assessment of 
the validity of bronchial provocation tests 
 
Authors: Vakali S, Vogiatzis I, Florou A, Zakynthinos S, Papadopoulos NG and Gratziou C 
 
Abstract 
Background: Diagnosis of exercise-induced bronchoconstriction (EIB) requires objective 
documentation with bronchial provocation tests (BPTs), since exercise-induced respiratory 
symptoms (EIRS) have poor diagnostic value. We aimed to assess EIRS, EIB and asthma in 
elite Greek athletes and evaluate the validity of BPTs in the diagnosis of airway 
hyperresponsiveness (AHR) in this population. Furthermore rhinitis and atopy were also 
assessed. 
Methods: Two hundred elite athletes (55 with a previous asthma diagnosis) completed a 
questionnaire. Skin prick tests, exhaled Nitric Oxide and spirometry were consecutively 
performed. EIB was objectively assessed by the methacholine test, the eucapnic voluntary 
hyperpnoea (EVH) test, the mannitol test and the exercise test.  
Results: EIRS and asthma-like symptoms were highly reported by athletes in both groups. 
Atopy was found in 43.8% of athletes without a previous asthma diagnosis and in 62.3% of 
athletes with asthma. AHR to methacholine had the highest prevalence among all the BPTs 
that were performed in athletes without a previous asthma diagnosis (63%) and in athletes 
with asthma (86%). Athletes with asthma had more frequently a positive result in 
methacholine and EVH challenges, as compared with athletes without a previous asthma 
diagnosis(P=0.012, P=0.017, respectively), whilst AHR to mannitol had a similar prevalence 
between the two groups. Report of EIRS, asthma-like symptoms, rhinitis and atopy were not 
associated with a positive BPT response.  
Conclusion: Screening elite athletes for EIB using BPTs is suggested irrespective of report of 
EIRS or a previous asthma diagnosis.  
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Exercise-induced bronchoconstriction (EIB) describes the transient airway narrowing that 
occurs after exercise, a phenomenon that occurs frequently among athletes who may not have 
a diagnosis of asthma or even have any respiratory symptoms.1 EIB is more common among 
endurance athletes, particularly swimmers and winter sport athletes, than in the general 
population.2  
   Diagnosing EIB or asthma in elite athletes is important given its potential detrimental 
impact on health and performance. Previous reports in athletic populations highlight that EIB 
and asthma are associated with increased morbidity and mortality.3 In terms of performance, 
EIB and asthma may reduce exercise capacity.4 Many studies support the need for screening 
for EIB and asthma in elite sport. 
   As exercise-induced respiratory symptoms (EIRS) have poor predictive value for making a 
diagnosis of EIB in athletes, documentation of variable airway obstruction is a requirement 
for the diagnosis of EIB in elite athletes5,6 and use of direct or indirect bronchial provocation 
tests (BPTs) is recommended. However, there are many issues that need to be addressed 
before such a policy could be feasible, including adoption of a standardized and reproducible 
test that is universally accepted, agreement on interpretation of test results, and cost-
effectiveness.7  
   Rhinitis has an added importance in the frequent report of combined nasal and asthmatic 
symptoms in patients with allergic rhinitis8 and the history of rhinitis should make the 
physician to test the possibility of concomitant asthma or airway hyperresponsiveness(AHR).9 
Allergic rhinitis has been observed as common among elite athletes.10 Of interest is also the 
association of physical exercise with the development of allergic sensitization in summer 
sport athletes. Zwick et al11 showed that in highly competitive swimmers the frequent 
exposure to chlorine and chlorine by-products in swimming pools during training and 
competition may facilitate sensitization to airborne allergens and AHR. 
   The aim of the present study was to investigate the presence of EIRS, EIB, asthma, atopy 
and allergic rhinitis in Greek elite athletes for the first time and secondly to further evaluate 
the validity, sensitivity and specificity of direct and indirect BPTs in the diagnosis of airway 
hyperresponsiveness in this population. 
 
Methods 
 
Subjects and study design 
 
  A group of 200 elite athletes, competing at high level National and Olympic Games 
participated in the study. Recruitment was through National sporting teams. The study was 
performed in collaboration with the Global Asthma and Allergy European Network 
(GA2LEN), the European network of centres of excellence in allergy and it was approved by 
the hospital and University Ethics Committee.  
   All athletes completed a demographic questionnaire on past and current respiratory 
symptoms, history of asthma, allergic rhinitis or other allergies, training and sport habits. The 
AQUA questionnaire12 (Allergy Questionnaire for Athletes) with supplement of some 
questions from the ECRHS questionnaire was used (see Appendix).13 According to history the 
population was subdivided in two groups; Group A: athletes with asthma and Group B: 
athletes without a previous diagnosis of asthma. Asthma was based on previous doctor 
diagnosis before entering the study (as ever diagnosed asthma). EIRS were defined as 
symptoms during or after exercise.  
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   Atopy, lung function and airway inflammation were assessed by skin prick tests to common 
allergens, spirometry and exhaled Nitric Oxide (eNO) respectively. All athletes had skin prick 
tests(SPT) according to European standards14 with the GA2LEN Pan-European panel of 
allergen extracts.15 Spirometry was performed according to ERS recommendations,16 using a 
dry wedge spirometer (Masterscreen, Jaeger, Hoechberg, Germany). Exhaled NO was 
measured using the portable Nitric Oxide Analyzer (NIOX MINO;Aerocrine, Solna, Sweden),  
according to ATS guidelines.17  
   To further investigate the validity of BPTs in detecting EIB we studied 111 athletes who 
voluntarily participated in the second phase of the study and they were tested by direct and 
indirect BPTs [Eucapnic voluntary hyperpnoea (EVH), mannitol and exercise test]. The tests 
were performed by at least 24h but less than 10 days. No test was performed if there was an 
upper or lower respiratory tract infection 8 weeks before entering the study. Elite athletes with 
at least one positive bronchial challenge were defined as EIB positive. 
 
Bronchial Provocation Tests 
 
Methacholine Challenge: Methacholine chloride were dissolved in normal saline solution to 
produce doubling concentrations range of 0.39-200mg/ml and immediately used for bronchial 
challenge. The first nebulisation administered was normal saline solution, and the post-saline 
solution FEV1 was used as the baseline for the calculation of subsequent percentage fall in 
FEV1. After challenge with saline solution, doubling concentrations of methacholine chloride 
were inhaled. An acceptable-quality FEV1 was obtained at each time point; otherwise the 
FEV1 manoeuvre was repeated. The challenge test was continued up to the dose of Mch that 
caused a 20% drop from baseline of FEV1 or until the maximum dose was inhaled. The 
cumulative dose causing a 20% fall in FEV1 (PD20) was calculated automatically by 
interpolation of the logarithmic dose response curve.  
Mannitol Challenge: A dry powder preparation of mannitol was delivered in gelatine capsules 
containing 0, 5, 10, 20 or 40mg (Osmohale, Pharmaxis Pharmaceuticals Ltd, UK). 
Consecutive doses of 0, 5, 10, 20, 40, 80, 160, 160 and 160mg (to a maximum cumulative 
dose of 635mg) were administered via an inhalator and a controlled deep inhalation to total 
lung capacity with 5 seconds of breath holding.18 A positive test was defined by a ≥15% fall 
in FEV1 at ≤ 635mg. The response was expressed as the cumulative dose that provoked a 15% 
fall in FEV1 (PD15) and as response-dose ratio (RDR; final percentage fall FEV1/total dose of 
mannitol administered).  
EVH Challenge: The EVH challenge was performed according to the method described by 
Anderson and Brannan.19 Briefly, athletes were required to breathe a dry gas mixture (21% 
O2, 5% CO2 and 74%N2) at room temperature for 6 min at a target ventilation rate equivalent 
to approximately 85% maximal voluntary ventilation (MVV). Target minute ventilation was 
calculated as 30xFEV1.19 FEV1 was measured before and at 3-, 5-, 10-, 15- and 20-min after 
EVH, with the best FEV1 recorded at each time point. The test was considered positive if a 
fall in FEV1 of ≥10% was observed over two consecutive time points compared with baseline. 
Ambient conditions in the laboratory were 21oC and 2% humidity 
Exercise test: The laboratory cycle test used the stepped protocol recommended by the ATS.20 
The athletes were asked to bike for 8 minutes in an electromagnetically braked cycle 
ergometer (Ergoline 800; Sensor Medics, Anaheim, CA, USA). Exercise intensity was set to 
elicit a heart rate of more than 85% of maximum for the final four minutes of exercise.  Post-
exercise spirometry was conducted in duplicate at 3-, 5-, 10-, 15- and 20-min recovery, with 
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the best FEV1 recorded at each time point. The test was considered positive if a fall in FEV1 
of ≥10% was observed over two consecutive time points compared with baseline.  
 
Statistical analysis 
 
Comparisons of variables of interest between Group A and Group B athletes were performed 
either by chi-square statistics of t-test as appropriate. Multivariate analysis (logistic regression 
model) assessed the existence of positive bronchial provocation challenge adjusted for EIRS, 
asthma like symptoms, rhinitis and atopy. All tests were 2-sided and the level of statistical 
significance was set at 5%. The magnitude of association is indicated by the respective Odds 
Ratio followed by the 95% Confidence Interval. All variables related to the airway responses 
to bronchial provocation challenges, pulmonary function tests and eNO levels were 
transformed into the natural logarithms in order to reduce the within subjects variability.  The 
dependence of airway response to bronchial provocation challenges and eNO to baseline 
characteristics, EIRS and asthma like symptoms, rhinitis, atopy, water sports and treatment 
were assessed by linear regression analysis model. The diagnostic value of bronchial 
provocation tests over the asthma diagnosis was assessed by sensitivity 
( true positive BPT
true positive BPT  false negative BPT
) and specificity ( true negative BPT
true negative BPT  false positive BPT
). All statistical 
analyses were performed using the Statistical Package for the Social Sciences, version 16.0 
(SPSS Inc., Chicago, IL, USA).  
 
Results 
 
Subject Characteristics 
 
The demographic characteristics of the study population in the 1st phase of the study are 
presented in Table 1a. We have studied 100 male and 100 female elite athletes. Fifty five 
(27.5%) had a previous diagnosis of asthma (Group A) and 155 athletes had a free history 
(Group B). Asthma diagnosis was more common in males compared with female athletes. 
Water sports were more common among athletes of Group A. No other differences in 
characteristics for age, smoking status and BMI were found between the 2 groups. 
   Exercise-induced respiratory symptoms (EIRS) were reported by 57% of the whole study 
population; 90.9% of Group A and 44.1% of Group B. Other asthma-like symptoms like 
shortness of breath, wheezing, cough and night respiratory symptoms were reported by a high 
proportion of Group A but they were also referred by Group B. Specifically, shortness of 
breath and cough were reported by 34.5% and 36.6% respectively by Group B.  
   Rhinitis symptoms were reported by 30.5% of the participants with no statistical difference 
being observed between the 2 groups. Surprisingly a high proportion of atopy (48.7%) was 
detected in our population with a higher percentage (62.3%) in Group A. A statistically 
significant association between EIRA and atopy atopy (P=0.01) and between EIRS and 
rhinitis symptoms (P=0.02) was found in the whole population. 
   According to history the athletes with asthma had mild severity of the disease and they 
received treatment; 47% were under inhaled corticosteroids (ICS) or combination treatment 
and 69% were under β2-agonists monotherapy.  
   There was no difference observed regarding the levels of eNO between the 2 groups (Table 
1a). Higher levels of eNO were related with the presence of atopy (P= 0.01) and with  rhinitis 
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symptoms (P= 0.049). The report of smoking was associated with lower levels of eNO (P= 
0.029). 
 
2nd phase of the study: Bronchial Provocation Tests for Airway Hyperresponsiveness 
 
From the 111 elite athletes who participated in the 2nd phase of the study 51 elite athletes were 
from Group A and 60 athletes from Group B. The participants were matched for age, sex, 
BMI and smoking status. Direct and indirect BPTs were performed without any complications 
by all participants. The methacholine test was performed by all participants, the EVH test by 
82 athletes, the mannitol test by 73 athletes and the exercise test by 58 athletes. The responses 
to BPTs are presented in Table 2a. 
   Elite athletes from Group A had more frequently a positive response to Mch and EVH 
challenges, as compared with athletes from Group B (P=0.012, P=0.017, respectively). No 
statistically significant difference was recorded for mannitol or exercise test between the two 
groups of athletes (Table 2a). A high percentage (63.3%) of Group B had a positive Mch 
challenge and 66.7% of that group had at least one positive response to direct or indirect 
challenges. Furthermore, 10 (27.8%) athletes from Group B had a positive response to EVH 
test and 8 (25%) athletes had a positive response to mannitol challenge. 
   The existence of reported EIRS or any other asthma-like symptoms, rhinitis and atopy were 
not associated with a positive BPT response (Table 2b). Seventeen (15%) elite athletes have 
reported EIRS but they did not have any positive BPT response, whereas 9 (8.1%) athletes 
had at least 1 positive BPT response without reporting any EIRS. 
   Linear regression analysis has shown a relation of the airway response to Mch (PD20) with 
wheezing (P<0.005) and of the airway response to EVH (ΔFEV1) with cough (P=0.017). 
Other factors such as age, gender, BMI, smoking status were not related with a positive 
response to BPTs.  
   Correlations among BPTs in our study population are shown in Figures 1a, 1b, 2a and 2c. 
EVH response (%drop in FEV1) was well correlated with Mch response (PD20) (r=-0.424, 
P=0.009, Figure 1a) and with mannitol response (PD15) (r=-0.659, P=0.038, Figure 1b) in 
Group A. Mannitol test was correlated with % drop of FEV1 to Mch test both in Group A 
(r=0.440, P=0.006, Figure 2a) and in Group B (r=0.425, P=0.019, Figure 2b). Not any other 
relevant correlation was found in Group B. 
   There was no concordance observed between the tests but only between the existence of a 
positive test response between mannitol and exercise BPT.   
   The sensitivity and specificity of each BPT for asthma diagnosis are presented in Table 3. 
Methacholine was the most sensitive and exercise test was the most specific challenge for the 
diagnosis of asthma in elite athletes.  
 
Discussion  
  
This is the first study investigating the prevalence of EIRS, EIB and the history of asthma, 
atopy and allergic rhinitis in Greek elite athletes who are competing at high standard national 
games. The important finding of our study is that a high proportion of Greek elite athletes 
without a previous asthma diagnosis report EIRS or other asthma-like symptoms without 
being tested with BPTs and they are competing being unaware that they might have EIB. Our 
findings are in line with previous studies,6,21 and highlight the need for screening elite athletic 
populations for the presence of EIB using BPTs, regardless of a previous asthma diagnosis or 
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report of EIRS, in order to improve athlete’s health and performance. It is important to notice 
that athletes may have a positive response to only one of these types of BPTs; therefore more 
than one type of test may be needed. Furthermore, as shown by Bougault et al, AHR is 
reduced or even normalized in elite swimmers when intense training is stopped for 15 days.22 
Consequently, ideally the testing of athletes with BPTs should be performed during a period 
of intense training.23 
   The diagnosis of asthma is common among Greek elite athletes (55 out of 200). This is an 
important finding if we consider that the prevalence of asthma in Greece ranges from 7.7% to 
11.5%.24 The high prevalence of asthma in our study could be related to the fact that a high 
percentage of athletes from Group A were male (65.5%). As the diagnosis of asthma is more 
prevalent among boys in the childhood25 they might be encouraged to engage in water sports, 
such as swimming, at an early age. Consequently, it is important to highlight that asthmatics 
can do exercise and compete at high standard national games. 
   We showed that a high percentage of athletes from Group B and the majority of athletes 
from Group A reported EIRS and asthma-like symptoms, like cough and shortness of breath. 
The use of self-reported respiratory symptoms to establish a diagnosis of EIB results in a 
high-frequency of both false-positive and false-negative diagnoses in endurance sports 
athletes.6 Self- reported symptoms are not specific enough for the diagnosis of AHR or EIB in 
athletes. Furthermore it has been shown that airway narrowing may occur in the absence of 
symptoms; thus an isolated symptom-based diagnosis of EIB is considered by some 
researchers to be unreliable.26 Our study is in line with the previously reported studies, since 
15% of our study population reported EIRS but they did not have a positive BPT response 
and 8% of elite athletes did not report EIRS but they had at least one positive BPT response. 
Furthermore, we found no association between EIRS and asthma-like symptoms with 
objective evidence of EIB. However, the high prevalence of EIRS and asthma-like symptoms 
among Greek elite athletes raises questions regarding misdiagnosis of EIB and suboptimal 
treatment of asthma among elite athletes.  
   According to our study, a high percentage of athletes had atopy (48.7%) and rhinitis 
symptoms (30.5%). Τhe overall prevalence of atopy and rhinitis in Greece24 range from 16% 
to 25.2% and from 21.3% to 24.2%, respectively. The high prevalence of atopic sensitization 
in our study population could be explained by the fact that we evaluated elite athletes mainly 
from water sports who train mostly outdoors, whereas exposure to airborne allergens is high. 
It has been previously reported that the presence of atopic sensitization could be a risk factor 
for the development of AHR and asthma.27 Moreover allergic athletes experience symptoms 
of upper and lower airways disease on exposure to both outdoor and indoor aeroallergens.28 
We found no association between AHR with atopy and with rhinitis symptoms, but the 
presence of EIRS was associated with atopy and with rhinitis symptoms in our study 
population. Allergic rhinitis has been previously shown to have negative effects on 
performance scores (ability to train and compete)29 and pollen monitoring may help allergic 
athletes to achieve peak performance under prophylactic measures.  
   Among all the BPTs that were performed in our study for the diagnosis of EIB, AHR to 
methacholine provocation test had the highest prevalence, in both groups of athletes. 
Regarding the diagnosis of EIB, a high prevalence of AHR to Mch has been reported only in 
winter athletes who however did not bronchoconstrict when exposed to indirect stimuli such 
as exercise, EVH or mannitol.30 In contrast, in summer sport athletes reported by Pedersen et 
al31 and Holzer et al32 there was a lower prevalence of AHR to Mch provocation and a higher 
prevalence of AHR to indirect stimuli. Nevertheless, in our study population, AHR to Mch 
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had the highest prevalence as compared to AHR to the indirect BPTs, and also a positive 
response to Mch detected almost all of the athletes with AHR to the indirect BPTs. However, 
reliance on a negative Mch test would frequently result in under-diagnosis of EIB.32,33 On the 
other hand a positive response to Mch test, in the absence of a positive response to an indirect 
stimulus may be an indicator of airway injury or remodeling, rather than currently active 
asthma or EIB.34 Mch provocation test is an easy to use test in the laboratory and it should be 
in the first line of assessment of EIB in elite athletes. In order to avoid over-diagnosis of EIB, 
a second line of investigation, using indirect BPTs, for accurate diagnosis of EIB is 
recommended. 
   The EVH is the test recommended by the International Olympic Committee Medical 
Commission when diagnosing EIB in athletes.35 In our study, AHR to the EVH test had the 
highest prevalence among the other indirect BPTs that were performed, especially in athletes 
from Group A. We showed that elite athletes from Group A had more frequently a positive 
response to EVH challenge, as compared with athletes from Group B. Furthermore, the EVH 
challenge correlated well with all other BPTs (direct and indirect), only in athletes from 
Group A. Consequently, we may hypothesize that, in contrast to the suggestion of Haantela et 
al36 regarding the two different clinical phenotypes of asthma in athletes, the EVH test might 
be the optimal indirect test for the diagnosis of EIB in elite athletes with a previous asthma 
diagnosis. In contrast, a similar percentage of AHR to mannitol and to EVH test was observed 
in elite athletes from Group B, thus concluding that in this group of athletes any one of the 
two indirect BPTs may be used for the diagnosis of EIB. 
   Inhaling dry powder mannitol increases the osmolarity of the airway surface and causes 
release of the same inflammatory mediators as EVH and exercise.37,38 A positive response to 
mannitol has been shown to identify individuals with asthma with EIB.39 On the other hand, 
previous studies have reported that some 30% of subjects with mild EIB are not identified 
with a mannitol test.33 In our study, in elite athletes from Group A we found a lower 
percentage of AHR to mannitol test as compared with AHR to EVH test. This latter finding 
might be explained by the fact that… 
   The prevalence of AHR to exercise test was very low in both groups of athletes. One of the 
most important reasons why exercise testing can lack the sensitivity for detecting EIB or 
asthma in elite athletes is the failure of the exercise stimulus to be intense enough to increase 
the ventilatory load to the necessary level in order to trigger bronchoconstriction.40 In our 
study, an ergometer bicycle was used and it seems that the majority of subjects were limited 
by leg fatigue rather than from ventilatory restriction. Sports-specific exercise that produces 
the symptoms, performed either in the laboratory or in the field, is probably the most relevant 
for testing elite athletes.41 However, environmental conditions, such as humidity and 
temperature levels, pollen count and pollution level may greatly affect the response to the 
field.42 
   A limitation of our study is that all the BPTs were not performed by all subjects. A further 
important limitation of our study is that almost half of athletes from Group A were under 
treatment with ICS and the relatively short ICS washout period (<3 days) may have led to 
some false-negative test results. Our approach to the duration of ICS washout was dictated by 
practical and ethical considerations with respect to withholding asthma medications. 
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Conclusion 
 
The high prevalence of EIRS and asthma-like symptoms among Greek elite athletes, although  
they are not specific for establishing the diagnosis of EIB, raises questions regarding 
misdiagnosis of EIB and suboptimal treatment of asthma in Greek elite athletes. The high 
proportion of EIB-positive elite athletes highlights the critical need for screening elite athletes 
for EIB using BPTs, irrespective of report of exercise-induced symptoms or a previous 
asthma diagnosis. We found no concordance between the pairs of BPTs, suggesting that Mch, 
EVH, mannitol and exercise challenge are not mutually interchangeable. This latter finding 
also implies that a negative result to e.g. EVH challenge should not deem an elite athlete 
negative for the presence of EIB and a second line of investigation should follow. The authors 
suggest that Mch should be in the first line for evaluation of EIB in elite athletes, regardless 
of a previous asthma diagnosis. As a second line of investigation and according to the 
facilities of each laboratory, a mannitol or a EVH test should be performed in elite athletes 
without a previous asthma diagnosis. In elite athletes with a previous asthma diagnosis the 
EVH should be preferred over the mannitol test, in order to confirm or exclude the diagnosis 
of EIB. The detection of previously unrecognized EIB may lead to improvements in athlete’s 
health and performance. 
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Table 1. Demographic characteristics and respiratory symptoms based on  
               Questionnaire 
 
 All Subjects  
(n= 200) 
Non-asthma  
(n= 145) 
Asthma  
(n= 55) 
Sex (male) 100 (50%) 64 (44.1%) 36 (65.5%) * 
Age(years) 21.6 (20.7-22.5) 22.1 (21.1-23.11) 20.4 (18.4-22.3) 
BMI (kg/m2) 21.9 (21.5-22.3) 21.8 (21.3 -22.3) 22.1 (21.4-22.8) 
Smoking(yes) 16 (8%) 12 (8.3%) 4 (7.3%) 
Water Sport 150 (70.5%) 95 (65.5%) 46 (83.6%) * 
>3 hours of training/ day 73 (36.5%)  53 (36,6%) 20 (36.4%) 
EIRS 114 (57%) 64 (44.1%) 50 (90.9%) ** 
Asthma like symptoms  
         Shortness of breath 88 (44%) 50 (34.5%) 38 (69.1%) ** 
         Wheezing 43 (21.5%) 20 (13.8%) 23 (41.8%) ** 
         Cough 92 (46%) 53 (36.6%) 39 (70.9%) ** 
         Night Symptoms 28 (14.1%) 10 (7%) 18 (32.7%) ** 
Rhinitis symptoms 61 (30.5%) 40 (27.6%) 21 (38%) 
Positive SPTs 96 (48.7%) 63 (43.8%) 33 (62.3%) * 
eNO, mean, 95%C.I. 16.0 
(14.53-17.62) 
15,70 
(14.09-17.50) 
16,85 
(13.64-20.81) 
Use of β2-agonists 38 (19%) 0 38 (69.1%)  
Use of ICS 26 (13%) 0 26 (47.3%)  
 
Values are in mean, 95%Confidence Intervals or N (%) 
BMI: Body Mass Index, EIRS: exercise-induced respiratory symptoms, SPTs: skin prick 
tests, eNO: exhaled Nitric Oxide, ICS: Inhaled Corticosteroids 
*: indicates statistically significant difference between non-asthma and asthma athletes. 
Gmean: Geometric Mean, CI: Confidence Interval 
 
 
Table 2a. Bronchial Provocation Tests in study population group  
 Without asthma (n=60) 
N (%) 
Previous Asthma 
diagnosis (n=51) 
N (%) 
P-value 
Methacholine (positive)  38 (63.3%) 44 (86.3%)   0.012* 
EVH (positive)  10 (27.8%) 26 (56.5%)   0.017* 
Mannitol (positive)  8 (25%) 12 (29.3%) 0.888 
Exercise (positive)  1 (4%) 3 (9.1%) 0.815 
At least 1 BPT positive  40 (66.7%) 46 (90.2%)   0.006* 
*: indicates statistically significant difference between non-asthma and asthma athletes. 
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Table 2b. Association of a positive bronchial provocation test and respiratory symptoms 
 OR (95% Confidence Interval) p-value 
EIRS 2.977 ( 0.739 - 11.989) 0.125 
Breathlessness 1.272 ( 0, 371- 4,364) 0.702 
Wheezing 1.693 (0.514 - 5.569) 0.386 
Cough 2.714 (0.978 - 7.532) 0.055 
Night symptoms 0.842 (0.139 - 5.096) 0.852 
Rhinitis 1.460 (0.488 - 4.373)  0.499 
Atopy 0.866 (0,301-2,486) 0.789 
EIRS: exercise-induced respiratory symptoms 
Night symptoms: Respiratory symptoms that awake the athlete during the night 
 
Table 3. Sensitivity and Specificity of Bronchial Challenges, based on previous diagnosis 
of asthma 
 
Bronchial Challenges Sensitivity (%) Specificity (%) 
Methacholine 86.3 36.7 
EVH 56.5 72.2 
Mannitol 29.3 75 
Exercise 9.1 96 
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1a. 
 
1b. 
 
Figure 1. Scatterplot of percentage fall in FEV1 by EVH in Group A vs. a) PD20 to 
methacholine challenge (mg) (rp: -0.424, p=0.009, n=37) and b) PD15 to mannitol 
challenge (mg) (rp: -0.659, p=0.038, n=10) 
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2a. 
 
  2b. 
 
Figure 2. Scatterplot showing the correlation between the percentage fall in FEV1 for 
mannitol vs. methacholine challenges in a) Group A (rp: -0.440, p=0.006, n=38) and b) 
Group B (rp: -0.425, P=0.019, n=30)  
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APPENDIX 
 Questionnaire GA2LEN 
